Słowacja - słowacki - myHealthbox

bayer ag - vodou dispergovateľný granulát - iodosulfuron-methyl-sodium 33 g/kg; thiencarbazone-methyl 25 g/kg; mefenpyr-diethy (safener) 150 g/kg

Słowacja - słowacki - myHealthbox

bayer ag - suspenzný koncentrát - amidosulfuron 25 g/l; iodosulfuron-methyl-sodium 6,25 g/l; 2,4-d 2-ehe 433 g/l; mefenpyr-diethyl (safener) 62,5 g/l

Unia Europejska - słowacki - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuskulárna blokáda - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Unia Europejska - słowacki - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - neuromuskulárna blokáda - všetky ostatné terapeutické produkty - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unia Europejska - słowacki - EMA (European Medicines Agency)

ucb pharma ltd - nátriumoxybutyrát - cataplexy; narcolepsy - Ďalšie lieky na nervový systém - liečba narkolepsie s kataplexiou u dospelých pacientov.

Unia Europejska - słowacki - EMA (European Medicines Agency)

correvio - vernakalant hydrochlorid - predsieňová fibrilácia - kardioterapia - rýchly prevod posledných vzniku fibrilácie predsiení na sínusový rytmus u dospelých:na non-operácie pacientov: fibrilácia predsiení .

Unia Europejska - słowacki - EMA (European Medicines Agency)

novo nordisk a/s - liraglutid - diabetes mellitus, typ 2 - lieky používané pri cukrovke - victoza je indikovaný na liečbu dospelých, dospievajúcich a detí vo veku 10 rokov a vyššie s nedostatočne kontrolovanou diabetes mellitus 2. typu ako doplnok stravy a exerciseas monotherapy keď metformín je považované za nevhodné z dôvodu neznášanlivosti alebo contraindicationsin okrem iné lieky na liečbu diabetu. pre študijné výsledky s ohľadom na kombinácie, vplyv na glykemický kontroly a kardiovaskulárne udalosti, a populácií študoval.

Unia Europejska - słowacki - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamid - epilepsie - antiepileptiká, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Unia Europejska - słowacki - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozín propándiol monohydrát - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lieky používané pri cukrovke - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. okrem iných liekov na liečbu diabetes mellitus 2. typu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Unia Europejska - słowacki - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozín propándiol monohydrát - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lieky používané pri cukrovke - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. okrem iných liekov na liečbu diabetes mellitus 2. typu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.